The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers CLR 1603, a phospholipid ether-paclitaxel conjugate, the company announced recently.

“This first issued patent under our CLR CTX Chemotherapeutic program provides Cellectar and any future partners intellectual property protection through at least November 2035, allowing significant runway for product development and commercialization,” Cellectar Biosciences President and CEO Jim Caruso said in a statement.

According to a release, the patent is based on one of the series of patent applications designed to protect both composition of matter and method of use for phospholipid drug conjugates (PDCs) developed with Cellectar’s proprietary phospholipid-ether delivery vehicle.